Raloxifene HCl

Category
Anti-osteoporatic
Product code
82640-04-8

Raloxifene HCl (Hydrochloride) is a selective estrogen receptor modulator (SERM) active pharmaceutical ingredient widely used for the prevention and treatment of osteoporosis in postmenopausal women and for reducing the risk of invasive breast cancer. By selectively modulating estrogen receptors in bone and breast tissue, Raloxifene HCl helps maintain bone density, reduce fracture risk, and provide protective effects against certain hormone-dependent cancers. Pharmaceutical companies formulate Raloxifene HCl into oral tablets, offering consistent dosing for long-term management.

Common Raloxifene HCl Uses and Treated Conditions

  • Postmenopausal Osteoporosis – Increases bone mineral density and reduces the risk of vertebral fractures.
  • Breast Cancer Risk Reduction – Lowers the incidence of invasive breast cancer in high-risk postmenopausal women.
  • Bone Health Maintenance – Supports ongoing bone integrity in postmenopausal patients.
  • Hormone-Related Therapy – Provides selective estrogen receptor modulation without stimulating breast or uterine tissue.

Why Choose Cambrex as Your Generic API Manufacturer?

As a leading generic API supplier, Cambrex manufactures Raloxifene HCl API in cGMP-compliant facilities, ensuring every batch meets stringent global quality and regulatory standards. Our technical expertise, robust quality systems, and proven regulatory track record empower clients to accelerate development timelines and achieve successful market approvals. We prioritize transparency, reliability, and scientific rigor at every stage of the supply chain making us your trusted generic API manufacturer.

For detailed chemical information on Raloxifene HCl, visit the official CAS website.

If you’d like more information or to request a sample, contact our Generic API team today.

Raloxifene HCl

Cambrex your API partner

Cambrex are a leading global supplier of generic APIs. From our sites in Italy, Sweden, and the USA, we work with generic drug companies well in advance of drug patent expiration, using high quality, non-patent-infringing processes to manufacture APIs.

Contact us